BR112021024491A8 - Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição - Google Patents
Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condiçãoInfo
- Publication number
- BR112021024491A8 BR112021024491A8 BR112021024491A BR112021024491A BR112021024491A8 BR 112021024491 A8 BR112021024491 A8 BR 112021024491A8 BR 112021024491 A BR112021024491 A BR 112021024491A BR 112021024491 A BR112021024491 A BR 112021024491A BR 112021024491 A8 BR112021024491 A8 BR 112021024491A8
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- infection
- disease
- improving
- preventing
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 1
- 229940031670 conjugate vaccine Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857534P | 2019-06-05 | 2019-06-05 | |
| PCT/US2020/035511 WO2020247301A1 (en) | 2019-06-05 | 2020-06-01 | Methods of treating patients with an immunogenic composition that protects against s. pneumoniae serotype 29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021024491A2 BR112021024491A2 (pt) | 2022-02-15 |
| BR112021024491A8 true BR112021024491A8 (pt) | 2023-04-11 |
Family
ID=73653320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024491A BR112021024491A8 (pt) | 2019-06-05 | 2020-06-01 | Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220218812A1 (https=) |
| EP (1) | EP3980050A4 (https=) |
| JP (1) | JP2022535064A (https=) |
| KR (1) | KR20220016964A (https=) |
| CN (1) | CN114025784A (https=) |
| AU (1) | AU2020289048A1 (https=) |
| BR (1) | BR112021024491A8 (https=) |
| CA (1) | CA3142697A1 (https=) |
| MX (1) | MX2021014948A (https=) |
| WO (1) | WO2020247301A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110225764A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 制备多糖-蛋白缀合物的方法 |
| CA3050120A1 (en) | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
| CN111065387B (zh) | 2017-09-07 | 2023-08-25 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
| WO2019050813A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
| TWI725359B (zh) | 2017-12-06 | 2021-04-21 | 美商默沙東藥廠 | 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法 |
| US12144855B2 (en) | 2018-04-30 | 2024-11-19 | Merck Sharp & Dohme Llc | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| EP3787673A4 (en) | 2018-04-30 | 2022-04-27 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| GEAP202415690A (en) | 2018-12-19 | 2024-01-10 | Merck Sharp & Dohme Llc | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311976A1 (en) * | 2009-10-19 | 2011-04-20 | Azienda Ospedaliero-Universitaria Meyer | Method for Streptococcus Pneumoniae diagnosis and serotyping |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| EP4488286A3 (en) * | 2016-03-31 | 2025-04-02 | Pogona, Llc | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| BR112019006278A2 (pt) * | 2016-09-30 | 2019-07-02 | Biological E Limited | composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína |
| ES3024474T3 (en) * | 2016-12-30 | 2025-06-04 | Vaxcyte Inc | Polypeptide-antigen conjugates with non-natural amino acids |
-
2020
- 2020-06-01 MX MX2021014948A patent/MX2021014948A/es unknown
- 2020-06-01 KR KR1020227000140A patent/KR20220016964A/ko not_active Withdrawn
- 2020-06-01 CA CA3142697A patent/CA3142697A1/en active Pending
- 2020-06-01 BR BR112021024491A patent/BR112021024491A8/pt unknown
- 2020-06-01 JP JP2021571699A patent/JP2022535064A/ja active Pending
- 2020-06-01 CN CN202080049226.4A patent/CN114025784A/zh active Pending
- 2020-06-01 US US17/614,876 patent/US20220218812A1/en not_active Abandoned
- 2020-06-01 AU AU2020289048A patent/AU2020289048A1/en not_active Abandoned
- 2020-06-01 WO PCT/US2020/035511 patent/WO2020247301A1/en not_active Ceased
- 2020-06-01 EP EP20819293.0A patent/EP3980050A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3142697A1 (en) | 2020-12-10 |
| BR112021024491A2 (pt) | 2022-02-15 |
| MX2021014948A (es) | 2022-01-24 |
| WO2020247301A1 (en) | 2020-12-10 |
| EP3980050A4 (en) | 2023-08-02 |
| JP2022535064A (ja) | 2022-08-04 |
| CN114025784A (zh) | 2022-02-08 |
| KR20220016964A (ko) | 2022-02-10 |
| EP3980050A1 (en) | 2022-04-13 |
| US20220218812A1 (en) | 2022-07-14 |
| AU2020289048A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024491A8 (pt) | Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição | |
| ECSP20032085A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos | |
| DOP2021000127A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso | |
| BR112013006396A2 (pt) | composições imunogênicas | |
| BR112021021637A2 (pt) | Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório | |
| BR112018000087A2 (pt) | composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas | |
| MX368897B (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. | |
| AR099445A1 (es) | Composiciones inmunogénicas que comprenden antígenos sacáridos capsulares conjugados y usos de los mismos | |
| BR112019004303A2 (pt) | composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma | |
| MX2020003756A (es) | Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile. | |
| BR112018069100A2 (pt) | uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae | |
| MX2020006662A (es) | Vacuna combinada intradermica contra mycoplasma y circovirus porcino. | |
| BR112022019207A2 (pt) | Composições de vacina para coronavírus e métodos de uso das mesmas | |
| WO2019157188A3 (en) | Compositions and methods for cross-protection against pneumococcal disease | |
| MX388528B (es) | Vacuna que comprende toxoides de clostridium. | |
| EA202191647A1 (ru) | Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения | |
| AR104514A1 (es) | Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |